Stockscreener 앱 받기
6.18
5.36%
-0.35
시장 영업 전:
5.45
-0.73
-11.81%
전일 마감가:
$6.53
열려 있는:
$6.17
하루 거래량:
43,278
Relative Volume:
0.46
시가총액:
$95.50M
수익:
-
순이익/손실:
$-14.88M
주가수익비율:
-6.3061
EPS:
-0.98
순현금흐름:
$-10.29M
1주 성능:
+17.49%
1개월 성능:
-5.65%
6개월 성능:
-31.03%
1년 성능:
-26.69%
1일 변동 폭
$6.04
$6.58
1주일 범위
$5.0595
$7.05
52주 변동 폭
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
명칭
Coya Therapeutics Inc
전화
650.739.3939
주소
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
COYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
6.18 | 95.50M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-04 | 개시 | D. Boral Capital | Buy |
Coya Therapeutics Inc 주식(COYA)의 최신 뉴스
Biotech Company Reports Promising Neurological Treatment in Clinical Study - streetwisereports.com
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN
Promising Outlook for Coya Therapeutics: Buy Rating Justified by Innovative Treatments and Pipeline Potential - TipRanks
Coya Therapeutics Announce Positive Interim Result from - openPR.com
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia – EventsNewsAsia.com - eventsnewsasia.com
Biotech Discovers Revolutionary Immunotherapy in Houston - streetwisereports.com
Coya stock in focus after interim results for dementia drug - Seeking Alpha
Coya Reports Positive Data From Proof Of Concept Open-label Study Of IL-2 And CTLA4-Ig Combo In FTD - Nasdaq
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - businessnews.ph
Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia - marketscreener.com
Revolutionary Frontotemporal Dementia Treatment Prevents Cognitive Decline in All Trial Patients - Stock Titan
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - Defense World
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? - Yahoo Finance
AI in Clinical Trials Market Growth 2025: Trends, Consumer - openPR.com
Coya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher – What’s Next? - Defense World
Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com
(COYA) Long Term Investment Analysis - news.stocktradersdaily.com
Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance
Coya Therapeutics stock hits 52-week low at $4.72 - Investing.com Australia
Coya Therapeutics stock hits 52-week low at $4.72 By Investing.com - Investing.com Canada
Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - The Joplin Globe
GMP Production of Exosomes Slated for Later This Year - streetwisereports.com
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - Defense World
Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases - Streetwise Reports
What is Chardan Capital’s Forecast for COYA FY2025 Earnings? - Defense World
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock - Yahoo Finance
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet - Yahoo Finance
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - Yahoo Home
Coya Therapeutics advances Treg exosome production By Investing.com - Investing.com South Africa
Coya Therapeutics advances Treg exosome production - Investing.com India
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Joplin Globe
Revolutionary Treg Exosome Treatment Could Transform Neurodegenerative Disease Therapy - Stock Titan
Agitation in Alzheimer's Disease Market: Analysis - openPR.com
(COYA) Trading Report - news.stocktradersdaily.com
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan Capital - Defense World
Coya Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. - Business Wire
Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
BTIG maintains Buy on Coya Therapeutics, target at $15 By Investing.com - Investing.com Canada
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Coya Therapeutics, Inc. SEC 10-K Report - TradingView
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results - Business Wire
Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering - Business Wire
Coya Therapeutics Announces Closing of $26.5 Million Private Placement - Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Where are the Opportunities in (COYA) - Stock Traders Daily
Coya Therapeutics (COYA) to Release Earnings on Tuesday - Defense World
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - The AM Reporter
Coya Therapeutics Inc (COYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Coya Therapeutics Inc 주식 (COYA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
0.24%
36.06%
자본화:
|
볼륨(24시간):